How PCSK9 Inhibitors Lower LDL Cholesterol (Cardiologist Explains)

The FDA has approved Lipfendra® (enlicitide), the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol. In this video, interventional cardiologist Philip Dattilo, MD, explains: • How LDL receptors remove cholesterol from the bloodstream • How PCSK9 causes LDL receptors to be degraded • How Repatha®, Praluent®, and Leqvio® work • How the new oral medication Lipfendra differs from injectable therapies • Primary versus secondary cardiovascular prevention • Absolute versus relative risk reduction • How to calculate number needed to treat • What we know—and do not yet know—about cardiovascular outcomes Lipfendra lowered LDL cholesterol by approximately 56% in adults with hypercholesterolemia and 59% in adults with heterozygous familial hypercholesterolemia in its pivotal trials. However, its cardiovascular-outcomes trial is still ongoing, so it has not yet been established that Lipfendra itself prevents heart attacks or strokes. Chapters 0:00 Intro 00:28 PCSK9 & Lipid Biology 03:55 PCSK9 Monoclonal Antibodies 05:31 Leqvio (Inclisiran) 06:16 Gene to Protein 07:46 Lipfendra (Enlicitide) 08:47 Clinical Effects of PCSK9 Inhibitors 09:03 Absolute vs. Relative Risk 09:57 Number Needed to Treat 10:33 Primary vs. Secondary Prevention 12:15 Cost Considerations 12:59 Outro #PCSK9 #Cholesterol #preventivecardiology #PCSK9 #Lipfendra #Enlicitide #Cholesterol #LDL #PreventiveCardiology #Cardiology #HeartHealth #Statins #Repatha #Leqvio #LipidManagement #HeartAttackPrevention #MedEd #FamilialHypercholesterolemia